Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-25T19:08:24.187Z Has data issue: false hasContentIssue false
  • English
  • Français

Risperidone in the treatment of psychoses in the elderly: a case report series

Published online by Cambridge University Press:  16 April 2020

R. Bullock  and
S. Libretto
R. Bullock
Affiliation:
Kingshill Research Centre, Victoria Hospital, Okus Road, Swindon, Wiltshire SN1 4JU, UK
S. Libretto*
Affiliation:
PO Box 79, Janssen-Cilag Ltd, Saunderton, High Wycombe, Buckinghamshire HP14 4HJ, UK
*
*Correspondence and reprints. E-mail address: slibrett@jacgb.jnj.com (S. Libretto).
Get access

Summary

Risperidone is one of the newer atypical antipsychotic agents, which combines potent serotonin and dopamine receptor antagonism. It shows efficacy against the positive and negative symptoms of schizophrenic psychoses and other psychotic conditions, and has a low propensity to cause extrapyramidal side effects. The aim of these case reports in elderly patients is to provide the benefit of personal experience with risperidone to the body of published literature and to demonstrate the types of patients that may benefit from treatment. These cases were compiled retrospectively from data collected on referral and during routine hospital appointments. This series covers four main areas of concern when treating the elderly: low-maintenance dosing minimising the likelihood of adverse events; successful treatment of patients previously uncontrolled and experiencing side effects with other antipsychotics; the possibility of intermittent rather than continuous treatment; and the benefits to patients, carers and the health services. At low doses, risperidone is an effective and well-tolerated treatment for psychoses in elderly patients that improves the quality of life for both patients and their caregivers.

Keywords

atypical antipsychoticelderlygeriatricpsychosesrisperidone
Type
Original article
Information
European Psychiatry , Volume 17 , Issue 2 , April 2002 , pp. 96 - 103
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS. 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allardyce, JMcKeith, IG. Dementia with Lewy bodies. Rev Clin Gerontology 1997 ; 7 : 163–70.CrossRefGoogle Scholar
Bowden, CRVoina, SJWoestenborghs, Rde Coster, RHeykants, J. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro. J Pharmacol Exp Ther 1992 ; 262 : 699–706.Google ScholarPubMed
Chouinard, GJones, BRemington, GBloom, DAddington, DMacEwan, GW et al. Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychophar-macol 1993 ; 13 : 25–40.Google Scholar
Committee on Safety of Medicines. Neuroleptic sensitivity in patients with dementia. Curr Prob Pharmacovig 1994 ; 20 : 61.Google Scholar
Davidson, MHarvey, PDVervarcke, JGagiano, CAde Hooge, JDBray, G et al. A long-term, multicentre, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry 2000 ; 15 : 506–14.3.0.CO;2-V>CrossRefGoogle Scholar
Davies, AAdena, MAKeks, NACatts, SVLambert, TSchweitzer, I. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther 1998 ; 20 : 58–71.CrossRefGoogle ScholarPubMed
Davis, JMJanicak, PG. Risperidone: Anew, novel (and better?) antipsychotic. Psychiatr Ann 1996 ; 26 : 78–87.CrossRefGoogle Scholar
Ereshefsky, LLacombe, S. Pharmacological profile of risperi-done. Can J Psychiatry 1993 ; 38 : S80–8.Google Scholar
Gilbert, PLHarris, MJMcAdams, LAJeste, DV. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995 ; 52 : 173–88.CrossRefGoogle ScholarPubMed
Grant, SFitton, A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994 ; 48 : 253–73.CrossRefGoogle ScholarPubMed
Hansen, LAGalasko, D. Lewy body disease. Curr Opin Neurol Neurosurg 1992 ; 5: 889–94.Google ScholarPubMed
Hoffman, DWWiner, MSTBartels, SOxman, TE. Therapeutic dose: serum level relationships of risperidone and active metabolite in a geriatric population. Psychopharmacol Bull 1995 ; 37 : 525.Google Scholar
Jeste, DVCaligiuri, MPPaulsen, JSHeaton, RKLacro, JPHarris, MJ et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995 ; 52 : 756–65.CrossRefGoogle ScholarPubMed
Lacro, JPEastham, JHJeste, DVLohr, JB. Newer antipsychotics and antidepressants for elderly people. Curr Opin Psychiatry 1996 ; 9 : 290–3.CrossRefGoogle Scholar
Lipski, PSDeath, JW. Risperidone in the treatment of agitated and aggressive patients with dementia. Aust J Ageing 1995 ; 13 : 151–4.CrossRefGoogle Scholar
Mackay, FJWilton, LVPearce, GLFreemantle, SNMann, RD. The safety of risperidone: a post-marketing study on 7684 patients. Human Psychopharmacol 1998 ; 13 : 413–8.3.0.CO;2-A>CrossRefGoogle Scholar
Madhusoodanan, SBrecher, MBrenner, RKasckow, JKunik, MNegrón, AE et al. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 1999 ; 7 : 132–8.CrossRefGoogle ScholarPubMed
Madhusoodanan, SBrenner, RAraujo, LAbaza, A. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995 ; 56 : 514–6.Google ScholarPubMed
Marder, SRMeibach, RC. Risperidone in the treatment of schizophrenia. Am J Geriatr Psychiatry 1994 ; 151 : 825–35.Google ScholarPubMed
McKeith, IFairbairn, APerry, R et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992 ; 305 : 673–8.CrossRefGoogle ScholarPubMed
Mimms, July 2000.Google Scholar
Netten, ADennett, JKnight, J. 1998. Unit costs of health and social care. Personal Social Services Research Unit, Canterbury, Kent (costs inflated to 1999 values using the Health Inflation Index).Google Scholar
Peuskens, J the Risperidone Study Group. Risperidone in the treatment of chronic schizophrenic patients: a multi-national, multi-centre, double-blind, parallel-group study versus halo-peridol. Br J Psychiatry 1995 ; 166 : 712–26.CrossRefGoogle Scholar
Piggott, MAPerry, EKMcKeith, IGMarshall, EPerry, RH. Dopamine D2 receptors in demented patients with severe neu-roleptic sensitivity. Lancet 1994 ; 343 : 1044–5.Google ScholarPubMed
Reilly, JGAyis, SAFerrier, INJones, SJThomas, SHL. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000 ; 355 : 1048–52.CrossRefGoogle ScholarPubMed
Sajatovic, MRamirez, LVernon, LBrescan, DSimon, MJurjus, G. Outcome of risperidone therapy in elderly patients with chronic psychosis. Int J Psychiatry Med 1996 ; 26 : 309–17.CrossRefGoogle ScholarPubMed
Schotte, AJanssen, PFMGommeren, WLuyten, WHML Van Gompel, PLesage, AS et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996 ; 124 : 57–73.CrossRefGoogle ScholarPubMed
Snoeck, EVan Peer, ASack, MHorton, M Mannens, Woes-tenborghs, R et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharma-cology 1995 ; 122 : 223–9.CrossRefGoogle ScholarPubMed
The Healthcare Financial Management Association & The Chartered Institute of Public Finance and Accountancy. November 1997. The Health Service Financial Database 1997, Institute of Public Finance Ltd, Croydon, (costs inflated to 1999 values using the Health Inflation Index).Google Scholar
Thomas, SHL. Drugs QT interval abnormalities and ventricular arrhythmias. Adv Drug React Toxicol 1994 ; 13 : 77–102.Google ScholarPubMed
Zarate, CABaldessarini, RJSiegel, AJNakamura, AMcDonald, JMuir-Hutchinson, LA et al. Risperidone in the elderly: a pharmacoepidemiological study. J Clin Psychiatry 1997; 58 : 311–7.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.